XNK Therapeutics will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center.
The proof of concept study is to determine feasibility to expand and activate NK cells from patients with AML using XNK’s platform. The goal is to establish patient selection criteria for a clinical trial using XNK’s platform and, ultimately, to develop novel therapeutic approaches for AML patients.
“Autologous treatments have a number of advantages. For example, they do not require prior conditioning, which can reduce the risk of serious infections, while at the same time potentially offering a persistent response,” says Michael Uhlin, CSO of XNK Therapeutics.
“XNK is currently active in the clinical development and manufacturing of autologous natural killer cell-based products by using its proprietary technology platform,” says Johan Liwing, CEO of XNK Therapeutics. “XNK has promising clinical data in multiple myeloma and the scientific rationale for applying XNK’s technology in other indications, including both hematological and solid cancers, is strong.”
Photo of Michael Uhlin: XNK Therapeutics